Search Results

You are looking at 51 - 60 of 1,114 items for :

  • "breast cancer" x
  • Refine by Access: All x
Clear All
Full access

Presenters: Melinda L. Telli and William J. Gradishar

Patients with HER2-positive breast cancer can now benefit from 4 newly approved agents shown to increase time to progression and, in some cases, overall survival (OS), as described at the NCCN 2021 Virtual Annual Conference by Melinda L. Telli, MD

Full access

Cindy Railton, Sasha Lupichuk, Jennifer McCormick, Lihong Zhong, Jenny Jaeeun Ko, Barbara Walley, Anil A. Joy, and Janine Giese-Davis

Introduction Women diagnosed with breast cancer (BC) in developed countries are living longer because of earlier diagnosis and more effective therapies leading to high numbers of survivors for cancer centers to follow. 1 , 2 In 2013, new BC

Full access

Katy E. Balazy, Cecil M. Benitez, Paulina M. Gutkin, Clare E. Jacobson, Rie von Eyben, and Kathleen C. Horst

Background Breast cancer is the second leading cause of cancer death for women in the United States, with an estimated 276,480 new diagnoses and 42,170 breast cancer–related deaths in 2020. 1 Despite mortality declining by 40% between 1989 and

Full access

Anthony A. Matthews, Sharon Peacock Hinton, Susannah Stanway, Alexander R. Lyon, Liam Smeeth, Krishnan Bhaskaran, and Jennifer L. Lund

Background Breast cancer remains the most common cancer among women worldwide. Earlier detection and the advent of new treatments have facilitated an increase in 5-year survival rate in the United States from 75% in the 1970s to 91% in the 2010s. 1

Full access

Ami M. Vyas, Hilary Aroke, and Stephen Kogut

related to insurance coverage, quality of care, workforce diversity, population health, and data collection, and has geared its efforts and substantial national funding to meet its goals. 1 Survival rates for breast cancer (BC), the most common cancer in

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

/print certificate. Release date: April 10, 2017; Expiration date: April 10, 2018 Learning Objectives: Upon completion of this activity, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Breast Cancer

Full access

Heidi Klepin, Supriya Mohile, and Arti Hurria

Oncol 2005 ; 16 : 1795 – 1800 . 6 Hurria A Naeim A Elkin E . Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists . Crit Rev Oncol Hematol 2007 ; 61 : 255 – 260 . 7 Pentheroudakis G

Full access

Shi-Yi Wang, Tiange Chen, Weixiong Dang, Sarah S. Mougalian, Suzanne B. Evans, and Cary P. Gross

have reported that ODX is cost-effective for all women with ER-positive, node-negative breast cancer. 8 – 13 However, several important methodologic limitations may have diminished the accuracy of previous cost-effectiveness analyses (CEAs). 14 First

Full access

Neelima Vidula, Leif W. Ellisen, and Aditya Bardia

Triple-negative breast cancer (TNBC), conventionally defined as breast cancer that does not express the estrogen receptor, progesterone receptor, and HER2, accounts for approximately twenty percent of breast cancer. 1 TNBC often presents in an

Full access

Megan C. Roberts, Allison W. Kurian, and Valentina I. Petkov

Background The Oncotype DX Breast Recurrence Score (RS) test is a 21-gene expression assay that became commercially available for clinical use in 2004. In patients with early-stage, hormone receptor−positive (HR+), HER2-negative breast cancer, RS